Clinical Trial Update: A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for GNC-038, a tetra-specific antibody, in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in Phase 1/2, currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• GNC-038

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Diffuse Large B-cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING